Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection

Gemma Banham, Alexandra Godlee, Sian Faustini, Adam Cunningham, Alex Richter, Lorraine Harper, Claire Backhouse (Contributor), Anna Casey (Contributor), Lynsey Dunbar (Contributor), Beena Emmanuel (Contributor), Megan Fahy (Contributor), Paul Moss (Contributor), Peter Nightingale (Contributor), Liz Ratcliffe (Contributor), Stephanie Stringer (Contributor)

Research output: Contribution to journalLetterpeer-review

58 Downloads (Pure)

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.
Original languageEnglish
Pages (from-to)2140-2142
Number of pages3
JournalJournal of the American Society of Nephrology
Volume32
Issue number9
Early online date2 Aug 2021
DOIs
Publication statusPublished - Sep 2021

Keywords

  • COVID-19
  • SARS-CoV-2
  • Antibody
  • Haemodialysis

Fingerprint

Dive into the research topics of 'Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection'. Together they form a unique fingerprint.

Cite this